Pr ecis: This study describes a mechanism through which an aggressive breast cancer activates pDC to promote a regulatory Th2 response, with implications for therapeutic targeting of a tumor-immune axis of growing recognition in its significance to malignancy.
Pr ecis: This report identifies a stromal cell population expressing the fibroblast activation protein (FAP), which is required for the desmoplastic response seen in many human carcinomas, also showing how FAP-expressing cells promote tumor growth via immune suppression and immune-independent remodeling of the stromal microenvironment. Pr ecis: This work describes a novel and clinically feasible strategy to facilitate the safe delivery of systemic viral anticancer therapies by using clinically available b3 integrin inhibitors to control the problematic inflammatory side effects induced by these effective anticancer agents.
2822
Definition of Prostaglandin E 2 -EP2 Signals in the Colon Tumor Microenvironment That Amplify Inflammation and Tumor Growth Xiaojun Ma, Tomohiro Aoki, Tatsuaki Tsuruyama, and Shuh Narumiya Pr ecis: These findings show how prostaglandin signaling in neutrophils and cancer-associated fibroblasts in the colorectal tumor microenvironment shape its inflammatory character, providing a mechanistic rationale to use EP2 antagonists as an alternative to aspirin for chemoprevention. Pr ecis: This important study shows how kinase upregulation in cancer cells can foster resistance to a kinase inhibitory drug, but that this upregulation also sensitizes cells to kinase-mediated toxicities that can be exploited by altering the drug dosing schedule, as a strategy to defeat the drug resistance.
2928
Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies Sandra Heskamp, Willemijn Hobo, Janneke D.M. Molkenboer-Kuenen, Daniel Olive, Wim J.G. Oyen, Harry Dolstra, and Otto C. Boerman
Pr ecis: PD-L1 expression in tumors is important for PD-1/PD-L1-based therapeutics and can be monitored noninvasively using SPECT/CT imaging, which may more readily enable patient selection for trials of this type of antibody-based immune checkpoint therapy. Pr ecis: This important study shows how the serine protease TMPRSS2 promotes the growth, invasion, and metastasis of prostate cancer cells via activation of the matrix protease matriptase, with implications that targeting these two proteases may offer new options to treat advanced prostate cancer.
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In normal epithelial cells, there is a balance of pro-and antiangiogenic and lymphangiogenic factors maintaining proper tissue homeostasis. During malignant transformation, early loss of one such factor, the lymphatic endothelial cell inhibitor SEMA3F, is necessary to enable pathologic lymphangiogenesis. As the squamous cell carcinoma cells develop a more aggressive phenotype, acquired expression of surface receptors like neuropilin 2 (NRP2), a receptor typically expressed at high levels on lymphatic endothelial cells, further facilitate tumor vascularity, expansion, and metastatic spread. Thus, expression of SEMA3F may function in both an autocrine and paracrine fashion through NRP2 to inhibit tumor growth, lymphatic invasion, and metastasis. For details, see article by Doçi and colleagues on page 2937.
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